Moleculin Q1 cash $16.8M; Annamycin CRc 62% in 1st/2nd line AML

Moleculin Biotech, Inc.

R&D expense $4.3M, G&A $2.4M; cash $16.8M expected to fund operations into Q4 2024.
MB-106 trial: 20 subjects evaluated; 45% CRc all lines (N=20); 62% CRc in 1st/2nd line (N=13).
USPTO issued patent for liposomal Annamycin composition; EMA granted Orphan Drug Designation for AML.
End of Phase 2 FDA meeting expected H1 2024; pivotal trial initiation planned H1 2025; NDA submission potential 2027.
Formed Annamycin Scientific Advisory Board with Dr. Martin Tallman as inaugural member.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Moleculin Biotech, Inc. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 13, 2024, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024 and recent operational highlights.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-016112

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.